Literature DB >> 3361230

Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I.

M L Henry1, B Everson, O D Ratnoff.   

Abstract

beta 2-Glycoprotein I (apolipoprotein H), a constituent of normal human plasma, has been shown to inhibit the generation of amidolytic activity in plasma that has been exposed to negatively charged agents. Studies with purified Hageman factor (factor XII) demonstrate that this inhibitory property is directed against the activation of Hageman factor. In this study beta 2-glycoprotein I inhibited the kaolin-induced generation of clot-promoting properties in solutions of Hageman factor. This effect was localized to an interaction between beta 2-glycoprotein I and kaolin. In contrast, once Hageman factor was activated by kaolin, its clot-promoting properties were not inhibited by beta 2-glycoprotein I. Further, beta 2-glycoprotein inhibited the generation of amidolytic activity against H-D-prolyl-L-phenylalanyl-L-arginine p-nitroanilide dihydrochloride in mixtures of Hageman factor and ellagic acid. The specificity of the action of beta 2-glycoprotein I was confirmed by its neutralization by immunoglobulin fractions of antiserums directed against this protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361230

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates.

Authors:  O D Ratnoff; B Everson; P Embury; N P Ziats; J M Anderson; M M Emanuelson; C J Malemud
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 3.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.

Authors:  D M Keeling; A J Wilson; I J Mackie; D A Isenberg; S J Machin
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

5.  Isolation from fetal bovine serum of an apolipoprotein-H-like protein which inhibits thymidine incorporation in fetal calf erythroid cells.

Authors:  Q G Li; R Blacher; F Esch; L F Congote
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

Review 6.  The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

Authors:  R Arreola-Diaz; A Majluf-Cruz; L E Sanchez-Torres; J Hernandez-Juarez
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.